Key result
Resuming anticoagulation in patients with abnormal D-dimer 1 month after withdrawal reduced recurrent venous thromboembolism compared to stopping (2.9% vs 15.0%).
Why the study?
Does D-dimer testing help determine the optimal duration of anticoagulant therapy in patients with a first unprovoked venous thromboembolism?
Population
608 patients with a first unprovoked venous thromboembolism who had received oral anticoagulation for at…
Comparison
D-dimer testing performed 1 month after… vs Not resuming anticoagulation in patients with…
Design
Review, Patients with abnormal D-dimer were randomized to resume or not resume…
Follow-up
average 1.4 years
Authors
Loading...
May support D-dimer-guided anticoagulation resumption after unprovoked VTE; leaves open confirmation before practice change.
Does D-dimer testing help determine the optimal duration of anticoagulant therapy in patients with a first unprovoked venous thromboembolism?
Absolute Event Rate: 2.9% vs 15%
D-dimer testing 1 month after anticoagulation withdrawal can identify patients at high risk for recurrent VTE who benefit from resuming anticoagulation.
Palareti et al. (2007) conducted a review in first unprovoked venous thromboembolism (n=608). Resumption of anticoagulation vs. Not resuming anticoagulation was evaluated on recurrent venous thromboembolism. Resuming anticoagulation in patients with abnormal D-dimer 1 month after withdrawal reduced recurrent venous thromboembolism compared to stopping (2.9% vs 15.0%).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: